New insights into small-cell lung cancer development and therapy
Yuwen Wang1, Songyun Zou1, Zhuyun Zhao1
1Department of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, Guangdong, China.
Abstract:
Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases; however, it is characterized by easy relapse and low survival rate, leading to one of the most intractable diseases in clinical practice. Despite decades of basic and clinical research, little progress has been made in the management of SCLC. The current standard first-line regimens of SCLC still remain to be cisplatin or carboplatin combined with etoposide, and the adverse events of chemotherapy are by no means negligible. Besides, the immunotherapy on SCLC is still in an early stage and novel studies are urgently needed. In this review, we describe SCLC development and current therapy, aiming at providing useful advices on basic research and clinical strategy.
Insights
Small-cell lung cancer (SCLC) is a challenging disease with high relapse rates and poor survival. Current treatments offer limited progress, highlighting the urgent need for novel therapeutic strategies and research advancements.
Area of Science:
- Oncology
- Pulmonology
- Cancer Research
Background:
- Small-cell lung cancer (SCLC) constitutes 15% of lung cancer cases.
- SCLC is known for frequent relapse and low survival rates, posing significant clinical challenges.
- Despite extensive research, effective management strategies for SCLC remain limited.
Purpose of the Study:
- To review the current understanding of SCLC development.
- To analyze existing therapeutic approaches for SCLC.
- To offer insights for future basic research and clinical strategies in SCLC management.
Main Methods:
- Literature review of SCLC development and treatment.
- Analysis of current first-line chemotherapy regimens (cisplatin/carboplatin with etoposide).
- Assessment of the current status and challenges of immunotherapy in SCLC.
Main Results:
- Standard first-line chemotherapy for SCLC has remained unchanged for decades.
- Current chemotherapy regimens are associated with significant adverse events.
- Immunotherapy for SCLC is in its nascent stages with unmet needs.
Conclusions:
- There is a critical need for advancements in SCLC treatment beyond current standards.
- Further research into SCLC development and novel therapeutic targets is essential.
- Improved clinical strategies are required to enhance outcomes for SCLC patients.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...